OncoSec Medical Company Profile (NASDAQ:ONCS)

About OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical logoOncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONCS
  • CUSIP: N/A
  • Web: www.oncosec.com
Capitalization:
  • Market Cap: $20.31 million
  • Outstanding Shares: 19,159,000
Average Prices:
  • 50 Day Moving Avg: $1.10
  • 200 Day Moving Avg: $1.29
  • 52 Week Range: $0.88 - $2.08
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.07
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.55 per share
  • Price / Book: 0.68
Profitability:
  • EBIDTA: ($23,410,000.00)
  • Return on Equity: -97.82%
  • Return on Assets: -83.81%
Debt:
  • Current Ratio: 7.59%
  • Quick Ratio: 7.59%
Misc:
  • Average Volume: 262,944 shs.
  • Beta: 1.76
  • Short Ratio: 10.87
 

Frequently Asked Questions for OncoSec Medical (NASDAQ:ONCS)

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) released its quarterly earnings results on Thursday, June, 9th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. View OncoSec Medical's Earnings History.

When will OncoSec Medical make its next earnings announcement?

OncoSec Medical is scheduled to release their next quarterly earnings announcement on Wednesday, June, 7th 2017. View Earnings Estimates for OncoSec Medical.

Where is OncoSec Medical's stock going? Where will OncoSec Medical's stock price be in 2017?

5 brokers have issued twelve-month price objectives for OncoSec Medical's shares. Their forecasts range from $5.00 to $6.00. On average, they expect OncoSec Medical's stock price to reach $5.67 in the next year. View Analyst Ratings for OncoSec Medical.

Who are some of OncoSec Medical's key competitors?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the folowing people:

  • Avtar S. Dhillon M.D., Independent Chairman of the Board
  • Punit S. Dhillon, President, Chief Executive Officer, Director
  • Richard B. Slansky, Chief Financial Officer
  • Sheela Mohan-Peterson J.D., Chief Legal and Compliance Officer
  • Sharron Gargosky PhD, Chief Clinical and Regulatory Officer
  • James Michael DeMesa M.D., Independent Director
  • Anthony E. Maida III, Ph.D., Independent Director

Who owns OncoSec Medical stock?

OncoSec Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (4.68%) and Vanguard Group Inc. (2.70%). View Institutional Ownership Trends for OncoSec Medical.

Who sold OncoSec Medical stock? Who is selling OncoSec Medical stock?

OncoSec Medical's stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for OncoSec Medical.

Who bought OncoSec Medical stock? Who is buying OncoSec Medical stock?

OncoSec Medical's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for OncoSec Medical.

How do I buy OncoSec Medical stock?

Shares of OncoSec Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of OncoSec Medical stock can currently be purchased for approximately $1.06.


MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)
Community Ranking:  5.0 out of 5 (    )
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  0 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OncoSec Medical (NASDAQ:ONCS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.67 (434.59% upside)

Analysts' Ratings History for OncoSec Medical (NASDAQ:ONCS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
5/18/2017Maxim GroupReiterated RatingBuy$5.00MediumView Rating Details
5/12/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/28/2016Ci CapitalInitiated CoverageBuyN/AView Rating Details
7/21/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for OncoSec Medical (NASDAQ:ONCS)
Earnings by Quarter for OncoSec Medical (NASDAQ:ONCS)
Earnings History by Quarter for OncoSec Medical (NASDAQ:ONCS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/7/2017        
10/13/2016Q416($0.32)($0.39)ViewListenView Earnings Details
6/9/2016Q316($0.43)($0.37)ViewN/AView Earnings Details
3/8/2016Q216($0.46)($0.42)ViewN/AView Earnings Details
12/8/2015Q116($0.48)($0.47)ViewN/AView Earnings Details
10/14/2015Q415($0.40)($0.48)ViewListenView Earnings Details
3/12/2015($0.02)($0.02)ViewN/AView Earnings Details
12/8/2014($0.02)($0.02)ViewN/AView Earnings Details
10/13/2014($0.01)($0.01)ViewN/AView Earnings Details
6/16/2014($0.01)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoSec Medical (NASDAQ:ONCS)
Current Year EPS Consensus Estimate: $-1.14 EPS
Next Year EPS Consensus Estimate: $-0.99 EPS

Dividends

Dividend History for OncoSec Medical (NASDAQ:ONCS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OncoSec Medical (NASDAQ:ONCS)
Insider Ownership Percentage: 11.53%
Institutional Ownership Percentage: 8.39%
Insider Trades by Quarter for OncoSec Medical (NASDAQ:ONCS)
Institutional Ownership by Quarter for OncoSec Medical (NASDAQ:ONCS)
Insider Trades by Quarter for OncoSec Medical (NASDAQ:ONCS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Punit DhillonInsiderBuy3,000$0.99$2,970.00View SEC Filing  
10/16/2015Punit DhillonCEOBuy10,000$4.25$42,500.00View SEC Filing  
6/10/2015Punit DhillonCEOBuy2,500$6.74$16,850.00View SEC Filing  
3/20/2014Anthony E Maida IIIDirectorBuy22,800$0.81$18,468.00View SEC Filing  
3/19/2014Punit DhillonCEOBuy50,000$0.80$40,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for OncoSec Medical (NASDAQ:ONCS)
Latest Headlines for OncoSec Medical (NASDAQ:ONCS)
Source:
DateHeadline
americanbankingnews.com logoOncoSec Medical Inc (ONCS) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 23 at 8:43 PM
americanbankingnews.com logoOncoSec Medical's (ONCS) "Buy" Rating Reiterated at Maxim Group
www.americanbankingnews.com - May 18 at 12:30 PM
americanbankingnews.com logoOncoSec Medical's (ONCS) Buy Rating Reiterated at Noble Financial
www.americanbankingnews.com - May 13 at 11:32 AM
americanbankingnews.com logoMaxim Group Reiterates Buy Rating for OncoSec Medical Inc (ONCS)
www.americanbankingnews.com - May 12 at 11:20 PM
prnewswire.com logoOncoSec to Host Third Quarter Financial Conference Call on June 1, 2017 - PR Newswire (press release)
www.prnewswire.com - May 12 at 12:34 AM
finance.yahoo.com logoOncoSec to Host Third Quarter Financial Conference Call on June 1, 2017
finance.yahoo.com - May 11 at 9:04 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE- Nvidia, Coty, Fossil, Time Inc ... - Nasdaq
www.nasdaq.com - May 10 at 7:14 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Nvidia, INC Research, Time Inc, Iconix Brand - Nasdaq
www.nasdaq.com - May 10 at 11:53 AM
streetinsider.com logoOncosec (ONCS) Announces Pact with Merck (MRK) to Evaluate Combination of ImmunoPulse IL-12 and KEYTRUDA ... - StreetInsider.com
www.streetinsider.com - May 10 at 11:53 AM
finance.yahoo.com logoOncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma
finance.yahoo.com - May 10 at 11:53 AM
prnewswire.com logoHow These Biotech Stocks are Faring? -- ContraVir Pharma, Intra-Cellular Therapies, Nivalis Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - May 2 at 4:49 PM
prnewswire.com logoOncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017 - PR Newswire (press release)
www.prnewswire.com - May 2 at 4:49 PM
finance.yahoo.com logoOncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017
finance.yahoo.com - May 2 at 11:11 AM
americanbankingnews.com logoOncoSec Medical (ONCS) Given Daily Media Sentiment Score of -0.12
www.americanbankingnews.com - April 29 at 8:22 AM
americanbankingnews.com logoOncoSec Medical Inc (ONCS) Expected to Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - April 28 at 12:48 AM
americanbankingnews.com logoOncoSec Medical (ONCS) Earning Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 25 at 8:00 PM
americanbankingnews.com logoOncoSec Medical (ONCS) Receiving Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 22 at 12:31 PM
americanbankingnews.com logoOncoSec Medical (ONCS) Given Daily News Impact Rating of 0.42
www.americanbankingnews.com - April 19 at 11:54 AM
americanbankingnews.com logoOncoSec Medical (ONCS) Getting Favorable Press Coverage, Study Finds
www.americanbankingnews.com - April 13 at 3:26 PM
americanbankingnews.com logo-$0.28 Earnings Per Share Expected for OncoSec Medical Inc (ONCS) This Quarter
www.americanbankingnews.com - April 6 at 6:15 PM
americanbankingnews.com logoMaxim Group Analysts Give OncoSec Medical Inc (ONCS) a $5.00 Price Target
www.americanbankingnews.com - April 3 at 7:34 PM
streetinsider.com logoOncosec Medical (ONCS) Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response ... - StreetInsider.com
www.streetinsider.com - April 3 at 9:30 AM
finance.yahoo.com logoOncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting
finance.yahoo.com - April 3 at 9:30 AM
finance.yahoo.com logoOncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017
finance.yahoo.com - March 28 at 9:55 AM
us.rd.yahoo.com logoOncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models
us.rd.yahoo.com - March 21 at 6:53 PM
seekingalpha.com logoOncoSec Medical's (ONCS) CEO Punit Dhillon on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 18 at 12:12 AM
streetinsider.com logoOncosec Medical (ONCS) Enters Technology Access Program Agreement with Inhibrx - StreetInsider.com
www.streetinsider.com - March 14 at 11:33 PM
us.rd.yahoo.com logoOncoSec Announces First Technology Access Program Agreement with Inhibrx
us.rd.yahoo.com - March 14 at 10:30 AM
finance.yahoo.com logoOncoSec to Present at Scientific and Investment Conferences in March
finance.yahoo.com - March 7 at 9:57 AM
thestreet.com logoBiotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot
www.thestreet.com - March 3 at 8:53 AM
prnewswire.com logoOncoSec to Host Second Quarter Financial Conference Call on ... - PR Newswire (press release)
www.prnewswire.com - March 2 at 7:12 PM
finance.yahoo.com logoOncoSec to Host Second Quarter Financial Conference Call on March 16, 2017
finance.yahoo.com - March 2 at 8:38 AM
finance.yahoo.com logoOncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma …
finance.yahoo.com - February 27 at 5:41 PM
streetinsider.com logoOncosec Medical (ONCS) Granted FDA Fast Track Designation for ImmunoPulse IL-12 to Treat Metastatic Melanoma
www.streetinsider.com - February 27 at 5:41 PM
us.rd.yahoo.com logoOncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab
us.rd.yahoo.com - February 27 at 5:41 PM
prnewswire.com logoOncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February ... - PR Newswire (press release)
www.prnewswire.com - February 25 at 1:08 AM
finance.yahoo.com logoOncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City
finance.yahoo.com - February 24 at 8:47 AM
streetinsider.com logoOncosec Medical (ONCS) Says Phase II Data Shows ImmunoPulse IL-12 in Combination with Pembrolizumab Increases Response Rates
www.streetinsider.com - February 23 at 7:06 PM
prnewswire.com logoOncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse ...
www.prnewswire.com - February 23 at 7:06 PM
us.rd.yahoo.com logoOncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients
us.rd.yahoo.com - February 23 at 7:06 PM
us.rd.yahoo.com logo11:32 am OncoSec Medical reports new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec's investigational intratumoral therapy, ImmunoPulse IL-12, and the approved anti-PD- 1, in patient
us.rd.yahoo.com - February 23 at 7:06 PM
seekingalpha.com logoOncoSec On Watch Before Upcoming Catalyst - Seeking Alpha
seekingalpha.com - February 16 at 11:37 PM
prnewswire.com logoOncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology ... - PR Newswire (press release)
www.prnewswire.com - February 9 at 1:01 AM
finance.yahoo.com logoOncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
finance.yahoo.com - February 8 at 7:59 PM
finance.yahoo.com logoOncoSec to Present at NobleCon13
finance.yahoo.com - January 27 at 12:10 AM

Social

Chart

OncoSec Medical (ONCS) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff